Pharmacom Accounts Payable from 2010 to 2026

PHMB Stock  USD 0.0001  0.00  0.00%   
Pharmacom Biovet's Accounts Payable is increasing over the years with slightly volatile fluctuation. Overall, Accounts Payable is expected to go to about 74.3 K this year. Accounts Payable is the amount Pharmacom Biovet owes to suppliers or vendors for products or services received but not yet paid for. It represents Pharmacom Biovet's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2010-12-31
Previous Quarter
70.8 K
Current Value
74.3 K
Quarterly Volatility
15.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Pharmacom Biovet financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharmacom Biovet's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 475.5 K or Total Revenue of 0.0, as well as many indicators such as . Pharmacom financial statements analysis is a perfect complement when working with Pharmacom Biovet Valuation or Volatility modules.
  
Build AI portfolio with Pharmacom Stock
Check out the analysis of Pharmacom Biovet Correlation against competitors.
For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.
Analyzing Pharmacom Biovet's Accounts Payable over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Accounts Payable has evolved provides context for assessing Pharmacom Biovet's current valuation and future prospects.

Latest Pharmacom Biovet's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Pharmacom Biovet over the last few years. An accounting item on the balance sheet that represents Pharmacom Biovet obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Pharmacom Biovet are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Pharmacom Biovet's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharmacom Biovet's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Pharmacom Accounts Payable Regression Statistics

Arithmetic Mean59,275
Geometric Mean49,446
Coefficient Of Variation26.06
Mean Deviation6,847
Median61,538
Standard Deviation15,445
Sample Variance238.6M
Range73.2K
R-Value0.52
Mean Square Error185.3M
R-Squared0.27
Significance0.03
Slope1,594
Total Sum of Squares3.8B

Pharmacom Accounts Payable History

202674.3 K
202570.8 K
201161.5 K
2010 1075.0

About Pharmacom Biovet Financial Statements

Pharmacom Biovet stakeholders use historical fundamental indicators, such as Pharmacom Biovet's Accounts Payable, to determine how well the company is positioned to perform in the future. Although Pharmacom Biovet investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pharmacom Biovet's assets and liabilities are reflected in the revenues and expenses on Pharmacom Biovet's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pharmacom Biovet. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable70.8 K74.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Pharmacom Biovet offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pharmacom Biovet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacom Biovet Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacom Biovet Stock:
Check out the analysis of Pharmacom Biovet Correlation against competitors.
For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. Anticipated expansion of Pharmacom directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pharmacom Biovet assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Pharmacom Biovet's market price often diverges from its book value, the accounting figure shown on Pharmacom's balance sheet. Smart investors calculate Pharmacom Biovet's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Pharmacom Biovet's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Pharmacom Biovet's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pharmacom Biovet should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.